Late-breaking and deferred publication abstracts
NSCLC, metastatic
LBA51 - Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC)

https://doi.org/10.1093/annonc/mdx440.054Get rights and content
Under an Elsevier user license
open archive

Cited by (0)